What kind of drugs does Valganciclovir belong to and its clinical pharmacological effects?

Valganciclovir (Valganciclovir) is an antiviral drug that belongs to the deoxynucleoside virus replication inhibitors. It is a prodrug that is rapidly hydrolyzed into the active ingredient Ganciclovir (Ganciclovir) in the body after oral administration. By inhibiting the activity of viral DNA polymerase, it blocks viral DNA synthesis, thereby inhibiting viral replication and spread. Due to the convenience of oral administration, Vancevir is easier to use clinically for long-term use than intravenous ganciclovir.

In terms of clinical pharmacological effects, Vancevir mainly targets cytomegalovirus (CMV) infection, and is especially suitable for the prevention and treatment of CMV in organ transplant recipients. It can effectively inhibit the replication of CMV, reduce the risk of infection after transplantation, and prevent organ rejection and complications. In high-risk patients, regular use of Vancevir can significantly reduce the rate of CMV infection and improve the success rate of transplantation and patient survival rate.

In addition, Vancevir also has significant efficacy in patients with low immune function, such as HIV infection or patients receiving long-term immunosuppressive treatment. By inhibiting viral replication, Vancevir can reduce CMV-related systemic symptoms and organ damage, such as retinitis, hepatitis, and gastrointestinal infections. Clinical practice shows that early application can reduce the risk of serious complications and improve patients' quality of life.

During use, the pharmacological effects of Vancevi are closely related to dosage, renal function and individual patient differences. Because it is primarily excreted by the kidneys, patients with renal insufficiency require dosage adjustments to avoid toxic effects such as bone marrow suppression (neutropenia, thrombocytopenia) or abnormal liver function. At the same time, blood routine and renal function should be monitored regularly to ensure the safety of medication and to maintain effective antiviral blood concentration. Through scientific use, Vancevi can exert stable and reliable clinical efficacy in the prevention and treatment of CMV.

Reference materials:https://www.drugs.com/